The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma.
aspirin
clopidogrel
incidence
occurrence
survival
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
04
09
2022
received:
06
08
2022
accepted:
07
09
2022
pubmed:
9
9
2022
medline:
15
12
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.
Identifiants
pubmed: 36075611
doi: 10.1111/eci.13870
pmc: PMC10078275
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13870Investigateurs
Aglitti A
(A)
Aliberti C
(A)
Baccarani U
(B)
Bhoori S
(B)
Borzio M
(B)
Brancaccio G
(B)
Burra P
(B)
Cabibbo G
(C)
Casadei Gardini A
(CG)
Carrai P
(C)
Cillo U
(C)
Conti F
(C)
Cucchetti A
(C)
D'Ambrosio R
(D)
Dell'Unto C
(D)
Di Costanzo Gg
(DC)
Di Sandro S
(DS)
Foschi Fg
(F)
Fucilli F
(F)
Gambato M
(G)
Gasbarrini A
(G)
Giuliante F
(G)
Ghinolfi D
(G)
Grieco A
(G)
Gruttaduria S
(G)
Guarino M
(G)
Kostandini A
(K)
Iavarone M
(I)
Lenci I
(L)
Levi Sandri Gb
(LS)
Losito F
(L)
Lupo Lg
(L)
Manzia Tm
(M)
Mazzocato S
(M)
Mescoli C
(M)
Miele L
(M)
Muley M
(M)
Persico M
(P)
Plaz Torres Mc
(PT)
Pompili M
(P)
Ponziani Fr
(P)
Rapaccini Gl
(R)
Rendina M
(R)
Renzulli M
(R)
Rossi M
(R)
Rreka E
(R)
Russo Fp
(R)
Sacco R
(S)
Sangiovanni A
(S)
Sessa A
(S)
Simonetti N
(S)
Sposito C
(S)
Tortora R
(T)
Trevisani F
(T)
Viganò L
(V)
Viganò M
(V)
Villa E
(V)
Vincenzi V
(V)
Violi P
(V)
Vitale A
(V)
Informations de copyright
© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Cancers (Basel). 2019 Jul 20;11(7):
pubmed: 31330817
Am J Cancer Res. 2016 Sep 01;6(9):2109-2116
pubmed: 27725915
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72
pubmed: 22753481
BMC Gastroenterol. 2020 Jan 9;20(1):6
pubmed: 31918672
Gastroenterology. 2013 Feb;144(2):323-332
pubmed: 23063971
Acta Pharmacol Sin. 2019 Jan;40(1):122-132
pubmed: 29925918
Cell Mol Immunol. 2015 May;12(3):264-8
pubmed: 25578311
Int J Oncol. 2012 Apr;40(4):1298-304
pubmed: 22179060
HPB (Oxford). 2021 Jun;23(6):915-920
pubmed: 33191108
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Int J Biol Markers. 2014 Sep 30;29(3):e215-23
pubmed: 24526315
Ann Surg Oncol. 2016 Dec;23(Suppl 5):874-883
pubmed: 27541812
Aliment Pharmacol Ther. 2021 Aug;54(4):356-367
pubmed: 34247393
Int J Cancer. 2019 Jul 1;145(1):267-273
pubmed: 30575949
World J Gastroenterol. 2018 Apr 21;24(15):1658-1665
pubmed: 29686473
Hepatology. 2022 Dec;76(6):1880-1897
pubmed: 35239194
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618961
Clin Transl Gastroenterol. 2021 Mar 23;12(3):e00324
pubmed: 33750746
J Natl Cancer Inst. 2012 Aug 22;104(16):1208-17
pubmed: 22888140
Infect Agent Cancer. 2018 Jun 08;13:20
pubmed: 29930697
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
J Natl Cancer Inst. 2012 Dec 5;104(23):1808-14
pubmed: 23197492
Ann Intern Med. 2016 Jun 21;164(12):836-45
pubmed: 27064677
Circulation. 2001 May 22;103(20):2501-7
pubmed: 11369692
Hepatology. 2017 Nov;66(5):1556-1569
pubmed: 28617992
N Engl J Med. 2020 Mar 12;382(11):1018-1028
pubmed: 32160663
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142758
Eur J Clin Invest. 2023 Jan;53(1):e13870
pubmed: 36075611
Cancer Prev Res (Phila). 2015 Dec;8(12):1156-62
pubmed: 26391917
Hepatology. 2019 May;69(5):2031-2047
pubmed: 30561038
JAMA Intern Med. 2019 May 1;179(5):633-640
pubmed: 30882847
Cancers (Basel). 2021 Jan 29;13(3):
pubmed: 33572776
Mol Oncol. 2016 Feb;10(2):195-212
pubmed: 26474915
J Clin Invest. 2019 Mar 25;129(5):1845-1862
pubmed: 30907747
J Clin Gastroenterol. 2022 Apr 1;56(4):369-373
pubmed: 33883511
JAMA Oncol. 2018 Dec 1;4(12):1683-1690
pubmed: 30286235
Life Sci. 2021 Jul 15;277:119612
pubmed: 33991548
Sci Rep. 2018 Mar 21;8(1):4968
pubmed: 29563592
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2784-2792.e7
pubmed: 32360983
Cancers (Basel). 2021 Dec 20;13(24):
pubmed: 34944996
JHEP Rep. 2019 Oct 25;1(6):448-459
pubmed: 32039397
J Formos Med Assoc. 2020 Jan;119(1 Pt 2):218-229
pubmed: 31104872
Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101545
pubmed: 33067170
Liver Int. 2021 Nov;41(11):2777-2785
pubmed: 34242482
Clin Gastroenterol Hepatol. 2021 Feb;19(2):246-258.e9
pubmed: 32407970
J Hepatol. 2013 Nov;59(5):1135-8
pubmed: 23742914
Oncotarget. 2016 Sep 13;7(37):60609-60622
pubmed: 27542264
AJR Am J Roentgenol. 2019 Sep;213(3):1-7
pubmed: 31120783
Hepatology. 2022 Aug;76(2):492-501
pubmed: 35100447